Magmaris

Implantation of the Absorb (Abbott Vascular, Santa Clara, CA, USA) everolimus-eluting poly-l-lactic BRS and Magmaris (Biotronik, Berlin, Germany) sirolimus-eluting magnesium bioabsorbable coating (BIOlute) Poly-l-Lactide (PLLA) BRS was carried out according to the above mentioned recommendations [13 (link)] after mandatory, successful (without any significant (over 20% of diameter) residual stenosis in angiographic assessment) lesion preparation with a balloon catheter (balloon:artery ratio 1:1 size by angiographic assessments with coexisting vessel diameter in a range from 2.7 mm up to 3.7 mm). Post-dilatation with an NC balloon, sized at least equal or up to 0.5 mm longer than the size of the scaffold, was obligatory. Post-dilatation was performed at high pressure (not less than 16 atm) If necessary, intravascular imaging was performed due to the decision of the operators. Standard pharmacotherapy was carried out following the current ESC/ESH guidelines for non-ST-segment elevation myocardial infarction (NSTEMI) [14 (link),15 (link)]: double antiplatelet therapy for 12 months.

Magmaris^® (Biotronik AG, Bulach, Switzerland) is a second-generation sirolimus-eluting RMS [7 (link)]. The device has a metallic bioresorbable backbone made from magnesium alloy, coated with BIOlute Poly-L-Lactide (PLLA) layer, where the antiproliferative drug is embedded with controlled release for up to 90 days [7 (link)]. The device has two tantalum markers, at the proximal and distal ends. The scaffold is placed between the distal and proximal radiopaque marker of the balloon. Previous in vitro and in vivo studies showed that about 95% of the magnesium is reabsorbed within 12 months [7 (link)]. The shorter time to resorption is due to a two-step degradation process, in which the magnesium alloy is replaced by a morphous calcium phosphate.